Ellen K Ritchie

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. pmc Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
    Ellen K Ritchie
    Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10065, USA
    Leuk Lymphoma 54:2003-7. 2013
  2. pmc Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ellen K Ritchie
    Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10065, USA
    Clin Interv Aging 7:165-73. 2012
  3. doi request reprint Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia
    Ellen K Ritchie
    Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    Curr Hematol Malig Rep 5:95-100. 2010
  4. doi request reprint Management of myelodysplastic syndromes in the geriatric patient
    Ellen K Ritchie
    Leukemia Program, Weill Cornell Medical College, 520 East 70th Street, Starr Room 351, New York, NY 10021, USA
    Curr Hematol Malig Rep 4:3-9. 2009
  5. doi request reprint Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 35:522-5. 2011
  6. pmc Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
    Joseph M Scandura
    Leukemia Program, Weill Cornell Medical College, New York, NY, USA
    Blood 118:1472-80. 2011
  7. pmc Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065, United States
    Leuk Res 36:407-12. 2012
  8. doi request reprint First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA
    J Clin Oncol 29:979-85. 2011
  9. doi request reprint Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 113:2504-11. 2008
  10. ncbi request reprint Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma
    Gail J Roboz
    Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 31:1141-4. 2007

Detail Information

Publications11

  1. pmc Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
    Ellen K Ritchie
    Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10065, USA
    Leuk Lymphoma 54:2003-7. 2013
    ..7% with a median OS of 177 days. Extramedullary toxicity was mild and the regimen was well tolerated for ongoing post-remission, outpatient maintenance cycles. Responses were durable for over 1 year...
  2. pmc Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ellen K Ritchie
    Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10065, USA
    Clin Interv Aging 7:165-73. 2012
    ..A new oral preparation of the drug is in development that will make the treatment more feasible and comfortable for elderly patients...
  3. doi request reprint Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia
    Ellen K Ritchie
    Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 10065, USA
    Curr Hematol Malig Rep 5:95-100. 2010
    ..Because it has never been shown that BSC as a sole therapeutic approach is kinder, less expensive, or better for older AML patients, it should be reserved for select clinical situations...
  4. doi request reprint Management of myelodysplastic syndromes in the geriatric patient
    Ellen K Ritchie
    Leukemia Program, Weill Cornell Medical College, 520 East 70th Street, Starr Room 351, New York, NY 10021, USA
    Curr Hematol Malig Rep 4:3-9. 2009
    ..Supportive care of these patients also could be improved to enhance their quality of life and functional performance...
  5. doi request reprint Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 35:522-5. 2011
    ..Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments...
  6. pmc Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
    Joseph M Scandura
    Leukemia Program, Weill Cornell Medical College, New York, NY, USA
    Blood 118:1472-80. 2011
    ..We conclude that epigenetic priming of intensive chemotherapy can be safely delivered in an attempt to improve response rates. This trial was registered at www.clinicaltrials.gov as NCT00538876...
  7. pmc Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065, United States
    Leuk Res 36:407-12. 2012
    ..There were no differences in 30- or 60-day mortality between the two groups...
  8. doi request reprint First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA
    J Clin Oncol 29:979-85. 2011
    ..This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351...
  9. doi request reprint Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 113:2504-11. 2008
    ..In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low-dose cytarabine in untreated patients aged >or=60 years with AML...
  10. ncbi request reprint Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma
    Gail J Roboz
    Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 31:1141-4. 2007
    ..Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting...
  11. ncbi request reprint Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 25:10-5. 2007
    ....